Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
EyeCon 2025 celebrates Visionary in Eye Care Resident Award winners | Ophthalmology Times
The recipients of this year’s Visionary in Eye Care Resident Recognition Awards were revealed at the Ophthalmology Times and Optometry Times EyeCon® 2025 conference, held September 26 and 27 at the Margaritaville Hollywood Beach Resort, in Hollywood, Florida. The program…
Q&A: Anat Loewenstein on the Ramin Tadayoni Award | Ophthalmology Times
Photo of Anat Loewenstein, MD, who served as the 2025 EURETINA president The Ramin Tadayoni Award is an initiative by the EURETINA board and Oculis company to honor the late Professor Ramin Tadayoni and support promising retinal research. This year,…
Q&A: Daniela Bacherini discusses using ultra widefield OCT to evaluate peripheral retinal degenerations | Ophthalmology Times
Photo of Daniela Bacherini at the 2025 EURETINA meeting Daniela Bacherini, MD, PhD, FEBO, from the University of Florence presented at the EURETINA 2025 meeting, focusing on ultra widefield peripheral OCT imaging of retinal degenerations. She explored how this advanced…
Looking ahead: Ophthalmologists envision a world without the toughest diseases | Ophthalmology Times
As Ophthalmology Times celebrates its 50th anniversary, we took the opportunity to ask a thought-provoking question to some of the field’s leading experts: “In a perfect world, if you could cure one eye disease or condition with the snap of…
Q&A: Boris Stanzel on the use of methotrexate in PVR cases | Ophthalmology Times
Photo of Boris Stanzel, MD, at the 2025 EURETINA meeting Professor Boris Stanzel, MD, presented research on methotrexate’s use in PVR retinal detachment surgery at the 2025 EURETINA congress, which was held in Paris, France. The study of 20 patients…
Increased complications in cataract surgery during the COVID-19 pandemic | Ophthalmology Times
(Image credit: AdobeStock/phonlamaiphoto) Canadian researchers recently reported significant increases in complications during cataract surgeries performed during the COVID-19 pandemic compared with the pre-pandemic period.1 First author Nathan Lee-Wing, BS, and MD candidate at the Max Rady College of Medicine, University…
FDA approves abbreviated new drug application from Amneal Pharmaceuticals for bimatoprost ophthalmic solution 0.01% | Ophthalmology Times
(Image Credit: AdobeStock) The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’ Abbreviated New Drug Application (ANDA) for bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL and 7.5 mL).1 An ANDA is a submission to the FDA that…
Luxa Biotechnology announces clinical trial results for treatment of AMD | Ophthalmology Times
(Image credit: ©Alex_Traksel/AdobeStock) Luxa Biotechnology LLC announced results from its phase 1/2a clinical trial titled “Safety and Tolerability of RPE Stem Cell-derived RPE (RPESC-RPE) Transplantation in Patients with Dry Age-related Macular Degeneration: Low Dose Clinical Outcomes.”1 The results were published…
Conavi Medical submits Novasight Hybrid IVUS/OCT System to FDA for 510(k) clearance | Ophthalmology Times
(Image Credit: AdobeStock/gguy) Conavi Medical has submitted its Novasight Hybrid™ IVUS/OCT intravascular imaging system to the US Food and Drug Administration (FDA) for 510(k) clearance for coronary applications. While optical coherence tomography (OCT) is traditionally used to monitor retinal diseases,…
OKYO Pharma details next clinical stage of urcosimod development | Ophthalmology Times
OKYO Pharma has announced its plans for the next stage of clinical development of urcosimod (formerly OK-101), its lead drug candidate to treat neuropathic corneal pain (NCP). NCP is a condition that causes severe pain and sensitivity of the eyes, face,…